Vasomedical is engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP® ) therapy systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system diseases that is cleared by the FDA and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance, and a staff training and maintenance programs designed to provide optimal patient outcomes. The Company also provides other non-invasive medical equipment including a full range of Biox™ ECG Holter monitors recorders and ambulatory blood pressure monitors.
Company Growth (employees)
Plainview, US
Size (employees)
218 (est)
Vasomedical was founded in 1994 and is headquartered in Plainview, US

Vasomedical Office Locations

Vasomedical has offices in Plainview, New York
Plainview, US
New York, US

Vasomedical Metrics

Vasomedical Summary

Market capitalization

$19.1 m

Closing share price

Vasomedical's current market capitalization is $19.1 m.

Vasomedical Financials

Vasomedical's revenue is $57.1 m in FY, 2015 which is a 63.3% increase from the previous period.
FY, 2013FY, 2014FY, 2015


$32.9 m$35 m$57.1 m

Revenue growth, %


Gross profit

$22.5 m$25.2 m$35.4 m

Operating expense total

$23.8 m$24.1 m$31.4 m


($1.3 m)$1.1 m$3.9 m

Net Income

($1.1 m)$1.1 m$3.8 m

Operating cash flow

($3.5 m)$1.2 m($7 m)

Vasomedical Market Value History

Vasomedical Online Presence

Vasomedical Company Life

You may also be interested in